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. 3 The International Society of Pediatric and Adolescent Diabetes (ISPAD) currently recommends MODY testing in cases of diabetes with a family history of diabetes in a first-degree relative, an absence of islet autoantibodies, and evidence of preserved beta-cell function. 4 ISPAD also recommends considering MODY in children diagnosed with T2DM who are neither obese nor have acanthosis nigricans, who come from an ethnic group with low prevalence of T2DM, and/or who have a strong family history of diabetes without obesity. 4 However, most children, including those who fulfill the above criteria, are not tested, resulting in estimates that >90% of MODY cases are missed. 3 The overarching rationale for MODY testing is that some MODY subtypes (HNF1A, HNF4A, KCNJ11, and ABCC8) may be manageable with oral hypoglycemic agents (sulphonylureas), allowing discontinuation of insulin. 5 This is cost-effective, improves metabolic control with less hypoglycemia, and, most importantly, dramatically improves quality of life. 6 In particular, a diagnosis of the GCK subtype leads to lifelong cessation of unnecessary insulin treatment. 7 Previous estimates of MODY prevalence in pediatric diabetes populations have varied widely, in part because of differences in selection criteria of cases, number of genes assessed, and method of genetic screening. [8] [9] [10] The development of massively parallel sequencing (MPS) means comprehensive, efficient, and cost-effective screening for MODY is now feasible in the clinical setting. 11 Two recent studies have used MPS to screen a clinic-based diabetes population. Both used targeted sequencing of all currently known MODY genes and also only sequenced antibody negative (Ab−) cases. 12, 13 Thus, to date, there has no comprehensive screening of a complete and unselected pediatric diabetes population.
The aim of our study was to use targeted MPS to determine the prevalence of variants in all known MODY genes in an entire pediatric diabetes population. We also compared the prevalence of MODY variants in this population with sequence data from a general population control cohort. Platform-related artifact was eliminated by excluding variants seen in >3 samples (either in the diabetes cohort or in the control samples).
| METHODS

| Study population
Variants with an allele count of >20 in Exome Aggregation Consortium (ExAC [http://exac.broadinstitute.org/]) were also excluded. (1) pathogenic, (2) likely pathogenic, (3) variant of unknown significance (VUS), (4) likely benign, and (5) benign.
| Variant classification
| Sanger sequencing
All pathogenic/likely pathogenic variants were validated by Sanger sequencing, except for two samples with insufficient DNA. Variants with alternate allele read depth ≤2 were also assessed, to validate the QC cut-off (i.e., ≥3 alternate alleles).
| Control data
An unrelated population cohort drawn from the Anglo-Australian
Osteoporosis Genetics Consortium (AOGC) and of similar ethnic background was used to assess prevalence of MODY variants, using exome data and similar analysis steps. Libraries were constructed using the Illumina TruSeq DNA sample preparation and TruSeq Exome capture kits all details regarding sequencing and annotation were as previously reported. 22 
| Statistical analysis
Frequencies of MODY variants in WACDD sequence data as a whole and by subgroups (Ab− T1DM, Ab+ T1DM, or T2DM) and AOGC control data were compared using χ 2 analysis in SPSS for Windows v.24.0.
3 | RESULTS Figure 1 ).
| Clinical cohort
| Sequencing results
| Coverage statistics
Mean depth of coverage across the 13 genes was 489-fold. Ninetytwo percent of bases had >10× coverage (Tables S1 and S2 , Supporting information). Ninety-three percent of HNF4A, GCK, HNF1A, and HNF1B (the genes which account for >95% of identified MODY cases 3 ) had average coverage depth >10×.
Coverage statistics for the control data are available in Reference 22 and for each MODY gene in Reference 23 .
Sanger sequencing validated the QC threshold of alternate allele read depth ≥3 reads and alternative allele ratio of >20%.
| Variants in MODY genes
Seventeen individuals in the sequenced cohort of 821 individuals had a pathogenic/likely pathogenic variant in a MODY gene (Table 1) .
These included all eight children previously diagnosed with MODY (based on clinical suspicion and previously confirmed genetically) and nine additional children not previously diagnosed with MODY (two with a diagnosis of T2DM, four with Ab− T1DM, and three with Ab+ T1DM The T1DM Ab− group was enriched with pathogenic/likely pathogenic variants compared to the Ab+ cohort (P < 0.001) and compared to the remaining sequenced cohort (P < 0.001). The T2DM group was also enriched with pathogenic/likely pathogenic variants compared with the remaining sequenced cohort (P < 0.001).
| Number of variants in different clinical subgroups
| Variants in control cohort
Three pathogenic/likely pathogenic variants were identified in the control population (0.3%) (all in HNF1A). Additionally, 34 subjects had VUS when considering all MODY genes, 18 of which were in the seven most studied MODY genes. Thus, 3.7% of control subjects had variants classified as categories 1 to 3 in a MODY gene (2.1% in the most studied MODY genes). Diabetes status was not known in the control population.
Pathogenic/likely pathogenic variants were significantly enriched in the sequenced cohort compared to the control population (P < 0.005). Considering each clinical subgroup individually, enrichment was seen in Ab− T1DM cases (P < 0.001) and T2DM cases (P < 0.001) but not Ab+ T1DM cases.
VUS within MODY genes were also significantly enriched in the diabetes cohort overall compared to the control cohort (P < 0.05), and in subgroup analysis were enriched specifically in Ab− T1DM and T2DM cases but not Ab+ T1DM cases.
| DISCUSSION
This is the first study to determine the prevalence of MODY variants in all known MODY genes in an unselected population-based pediatric diabetes cohort. Every child who had provided a DNA sample and consent was sequenced, regardless of antibody status, family history, or endogenous insulin production. Prevalence of pathogenic/likely pathogenic MODY variants in the sequenced cohort was 2.1%.
Although the entire WACDD cohort was recruited for this study, only two-thirds had both DNA and consent and could be sequenced;
and, as shown in Table 2 14 children with milder hyperglycemia and/or non-ketosis -most of whom will be presumed to have T2DM -are more likely to be managed locally and not referred for tertiary care. In this context, hyperglycemia in MODY is typically mild, particularly when due to mutations in GCK. Thus, there is the potential-both because a lower proportion of T2DM within WACDD were sequenced compared to other diabetes subtypes, and because fewer cases of T2DM in WA are referred to WACDD-for our data to underestimate the true prevalence of MODY in the entire pediatric diabetes population of WA. We found two of 39 presumed T2DM cases had a previously reported pathogenic variant in a MODY gene; both children were obese and had clinical signs of insulin resistance. With increases in childhood obesity, the traditional metabolic features used to distinguish T2DM from MODY 4 may prove less discriminatory. Given the prevalence of MODY variants shown here, and the increased ease of screening, it may prove both clinically advantageous and cost-effective to screen all pediatric T2DM diabetes cases even if current guidelines would not recommend testing. However, the generalizability of our results given both our small numbers and rapid increase in prevalence of pediatric T2DM driven by obesity remains unknown. ). One previous study has specified their criteria for variant classification. Johansson et al. 12 used a similar classification system to ACMG (as we have used here), although pathogenicity was determined using a system developed for cancer susceptibility genetic testing. 33 Other papers have not explicitly defined their criteria for allocating pathogenicity, which may contribute to the varying prevalence rates reported for MODY. MODY genes in the diabetes cohort compared to the control population is consistent with at least some of these variants being truly causative.
Our study did not assess structural variation in MODY genes in this population. Structural variation, including copy number variants (CNVs), is generally uncommon in MODY with the exception of HNF1B. Mutations in HNF1B typically account for fewer than 5% of MODY cases; however, approximately 40% of these are gene deletions. 35 Structural variants have also been described rarely in HNF1A
and GCK. 36 If a mutation in HNF1B was suspected clinically (e.g., presence of genitourinary abnormities), assessing for CNV (e.g., multiplex
ligation-dependent probe amplification) may be appropriate. We did not obtain complete capture of all exons of MODY genes; and if sequencing were provided as part of a clinical service (as opposed to a research project), sequencing of these regions by alternative methods would be required.
In conclusion, 2.1% of children and adolescents with diabetes recruited for this study from a large pediatric cohort had pathogenic/ likely pathogenic MODY variants, with MODY variants more likely in children previously diagnosed with T2DM or with Ab− T1DM. The observed prevalence, increasing access to affordable and rapid genetic screening, and significant clinical implications suggest that genetic screening for MODY may be both cost-effective and clinically justified for all children and adolescents with diabetes, particularly for those diagnosed with T2DM or Ab− T1DM.
